

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61K 31/557, C07C 405/00	A1	(11) International Publication Number: WO 96/10407 (43) International Publication Date: 11 April 1996 (11.04.96)
(21) International Application Number: PCT/US95/12171 (22) International Filing Date: 25 September 1995 (25.09.95) (30) Priority Data: 08/316,275 30 September 1994 (30.09.94) US 08/480,707 7 June 1995 (07.06.95) US (71) Applicant: ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134 (US). (72) Inventors: HELLBERG, Mark, R.; 5211 Overridge Drive, Arlington, TX 76107 (US). DEAN, Thomas, R.; 101 Meadow View Court, Weatherford, TX 76087 (US). ZINKE, Paul, W.; 4129 Willow Way Road, Fort Worth, TX 76133 (US). SELLIAH, Robert, D.; Apartment 3168, 5908 Beverly Drive W., Fort Worth, TX 76132 (US). BISHOP, John, E.; 878 Townsend Road, Groton, MA 01450 (US). (74) Agents: RYAN, Patrick, M. et al.; Alcon Laboratories, Inc., Patent Dept. Q-148, 6201 South Freeway, Fort Worth, TX 76134 (US).		(81) Designated States: AU, CA, CN, JP, MX, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: USE OF 9-DEOXY PROSTAGLANDIN DERIVATTVES TO TREAT GLAUCOMA (57) Abstract Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

USE OF 9-DEOXY PROSTAGLANDIN DERIVATIVES TO TREAT GLAUCOMA

Background of the Invention

The present invention relates generally to the treatment of glaucoma and
5 ocular hypertension by cyclopentane derivatives which are analogues of the
naturally occurring compounds known as prostaglandins. In particular, the
present invention relates to the use of 9-deoxy $\text{PGF}_{2\alpha}$ analogues and their
pharmaceutically acceptable salts, ester and amide derivatives for the treatment of
glaucoma and ocular hypertension. As used herein, the terms "prostaglandin" and
10 "PG" shall refer to prostaglandins and derivatives and analogues thereof, except as
otherwise indicated by context.

Naturally-occurring prostaglandins, including prostaglandins of the F series
(such as $\text{PGF}_{2\alpha}$), the E series (such as PGE_2) and the D series (such as PGD_2) are
known to lower intraocular pressure (IOP) after topical ocular instillation, but can
15 caused marked inflammation as evidenced by conjunctival edema or other
untoward effects such as conjunctival hyperemia. Many synthetic prostaglandins
have been observed to lower intraocular pressure, but such compounds also
produce the aforementioned side effects which greatly limit their clinical utility.
Attempts have been made by Stjernschantz et al. (US 5,321,128), Woodward et al.,
20 (US 5,093,329), Chan et al. (WO 92/08465) and Ueno et al. (EP 330 511 A2) to
reduce selectively or to eliminate altogether the side effects while maintaining the
IOP-lowering effect.

The Stjernschantz et al. publication is of particular interest as it
demonstrates that certain prostaglandins which retain the alicyclic rings
25 characteristic of the natural prostaglandins (PGA, PGB, PGD, PGE, PGF) but
which possess modifications in the omega chain maintain the intraocular pressure
lowering activity of the natural prostaglandins and have fewer adverse effects.


All the naturally-occurring prostaglandins known to reduce intraocular pressure, including prostaglandins of the F series (such as $\text{PGF}_{2\alpha}$), the E series (such as PGE_2) and the D series (such as PGD_2), have an oxygen substituent, either a hydroxyl or ketone, in the 9-position. All known synthetic prostaglandins which lower ocular pressure also have a substituent in the 9-position suggesting that substitution in the 9-position is important for activity. A further indication for the importance of the substituent in the 9-position is provided by Garst et al. (WO 94/08587 and WO 94/06432) who describe a series of 11-deoxy prostaglandin derivatives which retain intraocular pressure lowering activity. These prostaglandin derivatives retain the 9-hydroxy group of the natural prostaglandins indicating the necessity of this functionality for therapeutic efficacy.

Summary of the Invention

A series of 9-deoxy $\text{PGF}_{2\alpha}$ derivatives have been shown to bind to the FP prostaglandin receptor and stimulate second messenger expression linked to activation of an FP receptor. In particular, a series of 9-deoxy $\text{PGF}_{2\alpha}$ derivatives are useful in reducing the intraocular pressure and in treating glaucoma while exhibiting less adverse effects such as ocular inflammation and conjunctival hyperemia than those associated with the ocular use of the natural prostaglandins.

Detailed Description of the Invention

The 9-deoxy prostaglandin derivatives useful in the present invention have the general formula (I):



5 wherein:

$Y = C(O)NR_1R_2, CH_2OR_3, CH_2NR_1R_2, CO_2R_1, CO_2M$ where M is a cationic salt moiety;

R_1, R_2 (same or different) = H, C_1-C_6 alkyl or alkenyl, or C_3-C_6 cycloalkyl;

R, R_3 (same or different) = $C(O)R_4, H$;

10 $R_4 = C_1-C_6$ alkyl or alkenyl, or C_3-C_6 cycloalkyl;


$X = O, S(O)_n, CH_2$;

$n = 0, 1, \text{ or } 2$;

$A = CH_2CH_2, \text{ cis or trans } CH=CH, \text{ or } C\equiv C$;

$Z = CH_2CH_2, \text{ trans } CH=CH, \text{ or } C\equiv C$;

15 $W = (CH_2)_m \text{ Aryl}, (CH_2)_m \text{OAryl}$ where $m = 1-6$ and Aryl = phenyl, optionally substituted with halogen, hydroxy, alkoxy, haloalkyl, amino, or acylamino; or $W =$



wherein $V = H, \text{ alkyl, halogen, hydroxy, alkoxy, acryloxy, haloalkyl, amino, acylamino, and } L = CH_2, O, S(O)_m, CH_2CH_2, CH_2O, NR, CH=N, CH_2S(O)_m,$

$\text{CH}=\text{CH}$, CH_2NR where $m = 0-2$ and R is as defined above (hereafter, a "described bicyclic").

The preferred compounds of formula (I) are those wherein: $Y = \text{CO}_2\text{R}_1$; $\text{R}_1 = \text{CH}(\text{CH}_3)\text{CH}_3$, or H ; $X = \text{CH}_2$; $A = \text{cis } \text{CH}=\text{CH}$; $R = \text{H}$; $Z = \text{CH}_2\text{CH}_2$, or *trans* $\text{CH}=\text{CH}$; $W = (\text{CH}_2)_m \text{Aryl}$, or $(\text{CH}_2)_m \text{OAryl}$ where $m = 1-3$ and $\text{Aryl} = \text{phenyl}$, optionally substituted with CF_3 , Cl , F , or OMe ; or $W = \text{W}_2$ wherein $L = \text{CH}_2$ and $V = \text{H}$.

Some of the compounds of formula (I) are novel. These novel compounds are those of formula (I) wherein: $Y = \text{C}(\text{O})\text{NR}_1\text{R}_2$; CH_2OR_3 , or $\text{CH}_2\text{NR}_1\text{R}_2$; R_1, R_2 (same or different) = H , $\text{C}_1\text{-C}_6\text{alkyl}$, or $\text{C}_3\text{-C}_6\text{ cycloalkyl}$; R, R_3 (same or different) = H , $\text{C}(\text{O})\text{R}_4$; $\text{R}_4 = \text{C}_1\text{-C}_6\text{alkyl}$, or $\text{C}_3\text{-C}_6\text{ cycloalkyl}$; $X = \text{O}$, $\text{S}(\text{O})_n$, or CH_2 ; $n = 0, 1$, or 2 ; $A = \text{CH}_2\text{CH}_2$; *cis* or *trans* $\text{CH}=\text{CH}$; or $\text{C}\equiv\text{C}$; $Z = \text{CH}_2\text{CH}_2$, *trans* $\text{CH}=\text{CH}$, or $\text{C}\equiv\text{C}$; $W = (\text{CH}_2)_m \text{Aryl}$ or $(\text{CH}_2)_m \text{OAryl}$; $m = 1-6$; and $\text{Aryl} = \text{phenyl}$, optionally substituted with halogen, hydroxy, alkoxy, haloalkyl, amino, or acylamino. Also novel are those compounds of formula (I) wherein W is a described bicyclic.

The preferred novel 9-deoxy $\text{PGF}_{2\alpha}$ derivatives include those of formula (I) wherein: $Y = \text{CH}_2\text{OR}_3$ or $\text{C}(\text{O})\text{NR}_1\text{R}_2$; $\text{R}_1, \text{R}_2 = \text{H}$ or Me ; $\text{R}_3 = \text{C}(\text{O})\text{R}_4$; $\text{R}_4 = \text{C}(\text{CH}_3)_3$; $X = \text{CH}_2$; $A = \text{cis } \text{CH} = \text{CH}$; $R = \text{H}$; $Z = \text{CH}_2\text{-CH}_2$, *trans* $\text{CH} = \text{CH}$; $W = (\text{CH}_2)_m \text{Aryl}$ or $(\text{CH}_2)_m \text{OAryl}$ where $m = 1-3$ and $\text{Aryl} = \text{phenyl}$, optionally substituted with CF_3 , Cl , or F . Also preferred are those novel 9-deoxy $\text{PGF}_{2\alpha}$ derivatives of formula (I) wherein: $Y = \text{CO}_2\text{R}_1$; $X = \text{CH}_2$; $A = \text{cis } \text{CH}=\text{CH}$; $R = \text{H}$; $\text{R}_1 = \text{CH}(\text{CH}_3)_2$; $Z = \text{CH}_2\text{CH}_2$, or *trans* $\text{CH} = \text{CH}$; $W = \text{W}_2$ wherein $L = \text{CH}_2$ and $V = \text{H}$.






GB 1,539,368 assigned to Imperial Chemical Industries (ICI) describes alicyclic ring modified prostaglandin derivatives of the type useful in the present invention; however, the 9-deoxy PGF analogues disclosed in the ICI patent are used to inhibit the production of gastric acid or are effective in the induction of labor or parturition in mammals. The ICI patent is hereby incorporated by reference to the extent that it describes the preparation and pharmacological

profiles of these compounds.

The compounds of formula (I) can be prepared by employing appropriate variations to the pathway disclosed in GB 1,539,368. Such variations are known to those skilled in the art. For purposes of illustration only, the following Examples
5 1-4 are representative syntheses of the compounds of the present invention.


Table 1, below, lists compounds of the present invention which are referred to in the following Examples.

TABLE 1: REPRESENTATIVE COMPOUNDS

	COMPOUND NAME	COMPOUND STRUCTURE
II	(5Z)-(11R, 15R)-11,15-dihydroxy-3-oxa-17-phenyl-18,19,20-trinor-5-prostenoic acid isopropyl ester	
III	(5Z, 13E)-(11R, 15S)-11,15-dihydroxy-17-phenyl-18,19,20-trinor-5,13-prostadienoic acid	
IV	(5Z, 13E)-(11R, 15R)-16-(3-Chlorophenoxy)-11,15-dihydroxy-17,18,19,20-tetranor-5,13-prostadienoic acid isopropyl ester	
V	(5Z)-(11R, 15R)-11,15-dihydroxy-17-phenyl-18,19,20-trinor-5-prostenoic acid	
VI	(5Z)-(11R, 15R)-11,15-dihydroxy-15-(2-indanyl)-16,17,18,19,20-pentanor-5-prostenoic acid isopropyl ester	

In the following Examples 1-4, the following standard abbreviations are used: g = grams (mg = milligrams); mol = moles (mmol = millimoles); mL = milliliters; mm Hg = millimeters of mercury; mp = melting point; bp = boiling point; h = hours; and min = minutes. In addition, "NMR" refers to nuclear
5 magnetic resonance spectroscopy and "CI MS" refers to chemical ionization mass spectrometry.

**EXAMPLE 1: SYNTHESIS OF 9-DEOXY-13,14-DIHYDRO-3-OXA-17-PHENYL
PGF_{2α} ISOPROPYL ESTER**



A: Dimethyl-(2-oxo-4-phenylbutyl)phosphonate (2):

A solution of dimethyl methylphosphonate (26 mL, 0.23 mol) in 500 mL of anhydrous THF was cooled to -78 °C and n-BuLi (2.5 M in hexanes, 110 mL, 0.27 mol) was added dropwise at a rate such that the reaction temperature remained below -60 °C. The mixture was stirred for 10 min at -78 °C and then a solution of ethyl 3-phenylpropionate (35.2 g, 0.19 mol) in 60 mL of THF was introduced dropwise, while maintaining the reaction temperature below -60 °C. The resulting mixture was stirred at -78 °C for 30 min, then allowed to warm to room temperature (2 h) and was stirred at that temperature for 19 h. The reaction was quenched by careful addition of glacial acetic acid (18 mL) and was then poured in CH₂Cl₂/H₂O (200 mL each). The organic layer was separated and the aqueous layer was extracted (2 X 200 mL) with CH₂Cl₂. The organic layers were combined and washed sequentially with water (100 mL) and brine (100 mL) and then dried (MgSO₄). Filtration and solvent removal gave 57.4 g (93% crude yield) of 2 as a yellow liquid. This material was used without further purification. ¹H-NMR (CDCl₃) δ 7.24 (m, 5H), 3.74 (d, J = 12.0 Hz, 6H), 3.00 (d, J = 22.4 Hz, 2H), 2.92 (m, 4H).

B: (3aR, 4R, 5R, 6aS)-5-(Benzoyloxy)-4-[(E)-3-oxo-5-phenyl-1-pentenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (3):

A solution of the phosphonate 2 (22.2 g, 84 mmol) and LiCl (3.0 g, 75 mmol) in anhydrous THF (180 mL) was cooled to 0 °C and triethylamine (9.6 mL, 69 mmol) was added to it. A white suspension was formed. To this a solution of the aldehyde 1 (16.5 g, 60 mmol) in CH₂Cl₂ (50 mL) was added dropwise and the resulting mixture was stirred at 0 °C for 2 h. The reaction was quenched by adding 20 mL of a 0.1 N HCl solution and the mixture was partitioned between 100 mL of EtOAc and 50 mL of water. The organic layer was separated and the aqueous layer was extracted with 2 X 100 mL of EtOAc. The organic layers were combined, and washed with 50 mL of brine and dried (MgSO₄). Solvent removal afforded a yellow solid which was recrystallized from EtOAc to give 15 g (60%) of 3 as a white solid, mp 119 - 120 °C. ¹H-NMR (CDCl₃) δ 7.96 (d, J = 8.0 Hz, 2H), 7.44 (m, 3H), 7.24 (m, 5H), 6.65 (dd, J = 12, 6 Hz, 1H), 6.24 (d, J = 12 Hz, 1 H), 5.32

(m, 1H), 5.09 (m, 1H), 2.93 - 2.82 (m, 7H), 2.70 - 2.22 (m, 3H).

C: (3aR, 4R, 5R, 6aS)-5-(Benzoyloxy)-4-[(E)-(3S)-3-hydroxy-5-phenyl-1-pentenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (4):

A solution of 3 (14.4 g, 34.7 mmol) in 150 mL of anhydrous THF was cooled
5 to -23 °C and to it a solution of (-)-B-chlorodiisopinocampheylborane [(-)-DIP-Cl]
(16.7 g, 52 mmol) in 100 mL of anhydrous THF was added dropwise. The mixture
was stirred at -23 °C for 4 h and then quenched by adding 20 mL of CH₃OH. The
resulting solution was allowed to warm to room temperature and was stirred at
this temperature for 14 h. The reaction mixture was poured into 200 mL of
10 CH₂Cl₂/100 mL of water. The layers were separated and the aqueous layer was
extracted with CH₂Cl₂ (3 X 50 mL). The combined organic extracts were washed
with a saturated aqueous NH₄Cl solution (2 X 50 mL) and dried (MgSO₄).
Filtration and solvent removal gave a colorless liquid which was passed through a
short plug of silica gel to remove nonpolar-hydrocarbon contaminants. A mixture
15 of 4 and its diastereomeric allylic alcohol (94:6 ratio as determined by HPLC) was
isolated as a white solid (13.4 g, 92% combined yield). This mixture was subjected
to silica gel chromatography to afford 7.0 g of pure 4 as a waxy solid (R_f=0.18,
50% EtOAc /hexane; the R_f for minor diastereomer being 0.16 in the same solvent
system). ¹H-NMR (CDCl₃) δ 7.97 (d, J = 6 Hz, 2H), 7.40 (m, 3H), 7.16 (m, 5H), 5.64
20 (m, 2H), 5.25 (m, 1H), 5.06 (m, 1H), 4.15 (m, 1H), 2.95 - 2.50 (m, 7H), 2.20 (m, 1H),
1.80 (m, 3H).

D: (3aR, 4R, 5R, 6aS) Hexahydro-4-[(E)-(3S)-5-phenyl-3-(tetrahydropyran-2-yloxy)-1-pentenyl]-5-(tetrahydropyran-2-yloxy)-2H-cyclopenta[b]furan-2-one (6):

A mixture of lactone 4 (6.46 g, 15.5 mmol) and K₂CO₃ (2.14 g, 15.5 mmol) in
25 60 mL of CH₃OH was stirred at room temperature for 6 h. The reaction mixture
was poured into 100 mL 1 N HCl and extracted thoroughly with EtOAc (5 X 50
mL). Combined organic extracts were dried (MgSO₄) and concentrated and the
crude product mixture was purified by passage through a short plug of silica
(R_f=0.25, EtOAc) to yield 4.11 g of the dihydroxy compound 5.

30 A solution of 5 (4.11 g, 13.1 mmol) and dihydropyran (5.0 mL, 52.6 mmol)

in CH₂Cl₂ (50 mL) was cooled to 0 °C. A catalytic amount of *p*-TsOH (0.02 g, 0.1 mmol) was added and the mixture was stirred at 0 °C for 30 min and then quenched by adding saturated aqueous NaHCO₃ (10 mL). The layers were separated and the aqueous layer was extracted with 2 X 25 mL of CH₂Cl₂.

5 Combined organic extracts were dried (K₂CO₃), filtered and concentrated to afford a colorless oil which was subjected to chromatography on silica (R_f=0.31, 50% EtOAc/hexane). The bis-THP ether 6 (6.44 g, 86% yield from 4) was isolated as a colorless oil. ¹H-NMR (CDCl₃) δ (characteristic peaks only) 7.20 (m, 5H), 5.58 (m, 2H), 4.95 (m, 1H), 4.65 (m, 2H), 3.46 (m, 2H).

10 E: (3aR, 4R, 5R, 6aS) Hexahydro-4-[3(3R)-5-phenyl-3-(tetrahydropyran-2-yloxy)pentyl]-5-tetrahydropyran-2-yloxy)-2H-cyclopenta[b]furan-2-one (7):

A solution of the lactone 6 (6.44 g, 13.4 mmol) in 50 mL of EtOAc was hydrogenated in the presence of 10% Pd/carbon (0.15 g) at 40 psi in a Parr hydrogenation apparatus for 4 h. The reaction mixture was filtered through Celite
15 and the filtrate was concentrated to afford 7 (6.5 g, 99% yield) as a colorless oil. ¹H-NMR (CDCl₃) δ (characteristic peaks only) 7.22 (m, 5H), 5.00 (m, 1H), 4.76 (m, 2H), 3.52 (m, 2H).

F: (9S, 11R, 15R)-11,15-Bis-(tetrahydropyran-2-yloxy)-2,3,4,5,6,18,19,20-octanor-17-phenyl-9-(triethylsilyloxy)prostanol Triethylsilyl Ether (9):

20 The lactone 7 (6.5 g, 13.4 mmol) was dissolved in 100 mL of anhydrous THF and this solution was added dropwise to a cold (0 °C) suspension of lithium aluminum hydride (1.5 g, 40.2 mmol) in 100 mL of THF. The reaction mixture was allowed to warm to room temperature slowly and stirred at that temperature for 14 h. The reaction was cooled to 0 °C and quenched by the sequential addition
25 of 1.5 mL H₂O, 1.5 mL 15% aqueous NaOH and 4.5 mL H₂O. The resulting suspension was warmed to room temperature and filtered through a pad of anhydrous MgSO₄. The filter cake was washed thoroughly with EtOAc. Evaporation of the filtrate gave 5.59 g of the diol 8 (R_f=0.26, EtOAc) as a colorless oil.

30 A solution of diol 8 (5.59 g, 11.5 mmol), triethylamine (9.6 mL, 69 mmol),

chlorotriethylsilane (5.84 mL, 34.5 mmol) and *N,N*-dimethylaminopyridine (0.1 g, 0.83 mmol) in 200 mL of CH₂Cl₂ was stirred at room temperature for 12 h. The reaction mixture was poured into 100 mL of H₂O, the layers were separated and the aqueous layer was extracted with 2 X 25 mL of CH₂Cl₂. The combined organic
5 layers were dried (MgSO₄), filtered and concentrated to afford a yellow liquid which was chromatographed on silica (R_f=0.25, 10% EtOAc/hexane). Bis-silyl ether 9 (8.44g, 88% yield from 7) was obtained as a slightly yellow oil.

G: (9S, 11R, 15R)-11,15-Bis-(tetrahydropyran-2-yloxy)-2,3,4,5,6,18,19,20-octanor-17-phenyl-9-(triethylsilyloxy)prostanal (10):

10 A solution of oxalyl chloride (2.7 mL, 29.5 mmol) in anhydrous CH₂Cl₂ (20 mL) was cooled to -78°C under N₂ and to it a solution of DMSO (4.1 mL, 59.0 mmol) in CH₂Cl₂ (5 mL) was added dropwise. After 3 min, a solution of 9 (8.49 g, 11.8 mmol) in 25 mL of CH₂Cl₂ was added in a dropwise manner to the reaction mixture. The resulting mixture was stirred at -78 °C for 3 h at which time
15 triethylamine (8.2 mL, 59.0 mmol) was added and the resulting slurry was allowed to warm to room temperature over a period of 15 min. The reaction mixture was partitioned between 100 mL of EtOAc and 25 mL of water. The aqueous layer was extracted with 50 mL of EtOAc. The combined organic layers were washed with brine and dried over MgSO₄. Filtration and concentration gave a yellow oil
20 which was subjected to chromatography on silica gel (R_f 0.53 30% EtOAc/hexane) to yield 10 (8.0 g, 99% yield) as a slightly yellow oil. ¹H-NMR (CDCl₃) δ (characteristic peaks only) 9.80 (s, 1H), 7.24 (m, 5H), 4.62 (m, 2H), 0.89 (distorted t, 9H), 0.57 (distorted q, 6H).

H: (5Z)-(9S, 11R, 15R)-11,15-Bis-(tetrahydropyran-2-yloxy)-2,3,4,18,19,20-hexanor-17-phenyl-9-(triethylsilyloxy)-5-prostenoic Acid Methyl Ester (11):

A solution of 18-crown-6 (10.6 g, 40.2 mmol), and bis (2,2,2-trifluoroethyl)-(methoxycarbonylmethyl)phosphonate (4.7 g, 14.7 mmol) in anhydrous THF (10 mL) was cooled to -78 °C under a N₂ atmosphere. Potassium bis(trimethylsilyl) amide (0.5 M in toluene, 29.4 mL, 14.7 mmol) was added to the above mixture and the solution was stirred for 15 min. A solution of the aldehyde 10 (8.0 g, 13.4 mmol) in 50 mL of THF was added dropwise over a period of 15 min. The resulting mixture was stirred at -78 °C for 1.5 h and was then brought to 0 °C over a period of 30 min. The reaction was quenched at 0 °C with saturated aqueous NH₄Cl (100 mL) and the mixture was allowed to warm to room temperature. The layers were separated and the aqueous layer was extracted with 2 X 50 mL of EtOAc. The combined organic layers were washed with 2 X 50 mL of brine and dried (MgSO₄). Filtration and solvent removal gave a yellow slurry which was passed through a short plug of silica gel to afford a mixture of 11 and its *E* isomer (9:1 ratio respectively, 8.1 g, 93% combined yield). Isomers were separated by chromatography on silica gel (*R_f*=0.58, and 0.54, for 11 and the minor isomer respectively, 30% EtOAc/hexane); 4.32 g of pure 11 was isolated. ¹H-NMR (CDCl₃) δ (characteristic peaks only) 7.25 (m, 5H), 6.42 (m, 1H), 5.78 (d, *J* = 11 Hz, 1H), 4.65 (m, 2H), 3.68 (s, 3H), 0.93 (distorted t, 9H), 0.58 (distorted q, 6H).

I: (5Z)-(9S, 11R, 15R)-11,15-Bis-(tetrahydropyran-2-yloxy)-2,3,4,18,19,20-hexanor-9-hydroxy-17-phenyl-5-prosten-1-ol (13):

A solution of 11 (4.32 g, 6.6 mmol) in 50 mL of anhydrous THF was cooled to 0 °C and DIBAL-H (1.5 M in toluene, 13.2 mL, 19.8 mmol) was added to it. The resulting mixture was stirred at the same temperature for 2 h. The reaction was quenched by the careful addition of 100 mL of a saturated aqueous solution of sodium potassium tartrate. The resulting biphasic mixture was stirred vigorously for 1h. The layers were separated and the aqueous layer was extracted with 3 X 50 mL of EtOAc. The combined organic layers were dried (MgSO₄), filtered and concentrated to afford 4.23 g (quantitative yield) of 12 (*R_f*=0.33, 30% EtOAc/hexane) as a colorless liquid.

A solution of the allyl alcohol **12** (0.63 g, 1.0 mmol) in 5.0 mL of THF was treated with tetrabutylammonium fluoride (1.0 M in THF, 1.5 mL, 1.5 mmol) at room temperature for 5 min. The reaction mixture was poured into brine (10 mL) and the aqueous layer was extracted with ether (4 X 10 mL). The combined
5 organic layers were dried (MgSO₄), filtered, and concentrated. The crude was purified by chromatography on silica gel (R_f=0.15, 50% EtOAc/hexane) to afford **13** (0.48 g, 93% yield) as a colorless oil.

I: (5Z)-(9S,11R,15R)-11,15-Bis-(tetrahydropyran-2-yloxy)-9-hydroxy-3-oxa-17-phenyl-18,19,20-trinor-5-prostenoic Acid Isopropyl Ester (14):

10 A biphasic mixture of the diol **13** (0.48 g, 0.93 mmol), toluene (5 mL), tetrabutylammonium hydrogensulfate (30 mg, 0.08 mmol), and aqueous NaOH (25% w/v, 5 mL) was cooled to 0 °C while stirring vigorously. To this mixture isopropyl bromoacetate (0.5 g, 2.8 mmol) was added dropwise. The mixture was stirred at 0 °C for 30 min and then at room temperature for 30 min. The layers
15 were separated at this time and the aqueous layer was extracted with 10 mL of toluene. The combined organic layers were washed with water, and brine (5 mL each), dried (MgSO₄), and concentrated. The crude mixture was chromatographed on silica (R_f=0.45, 50% EtOAc/hexane) to afford **14** (0.37 g, 65% yield) as a colorless oil. ¹H-NMR (CDCl₃) δ (characteristic peaks only) 7.25 (m, 5H), 5.72 (m,
20 2H), 5.14 (distorted septet, 1H), 4.63 (m, 2H), 3.48 (m, 2H), 1.25 (d, J = 6 Hz, 6H).

K: (5Z)-(9R,11R,15R)-11,15-Dihydroxy-9-iodo-3-oxa-17-phenyl-18,19,20-trinor-5-prostenoic Acid Isopropyl Ester (15):


A solution of the ester **14** (0.265 g, 0.433 mmol) in anhydrous pyridine (2.0 mL) was cooled to 0 °C and to it methanesulfonyl chloride (0.07 mL, 0.866 mmol)
25 was added dropwise. The resulting mixture was kept at 0 °C for 30 min and then allowed to warm to ambient temperature (2 h). At this time the reaction mixture was transferred via cannula to a flask containing a suspension of tetrabutylammonium iodide (0.79 g, 2.16 mmol) in toluene (5.0 mL), and the resulting solution was heated at 60 °C for 3 h. The reaction mixture was then cooled to
30 room temperature and partitioned between ethyl acetate (100 mL), and 10%

solution of NaHSO₄ (50 mL). The organic layer was washed with saturated CuSO₄ (2 X 10 mL) dried (Na₂SO₄) filtered and concentrated. The crude yellow liquid was used in the next step.

The crude mixture obtained above was taken up in 20 mL of methanol and 0.5 mL of water, cooled to 0 °C and to it 1.0 mL of concentrated HCl was added. The mixture was stirred at 0 °C for 15 min and then at room temperature for an additional 30 min. The reaction was then quenched by adding solid NaHCO₃ and transferred to a separatory funnel containing 20 mL each of CHCl₃ and water. The layers were separated and the aqueous layer was extracted with 3 X 20 mL of CHCl₃. The combined organic layers were washed with 2 X 10 mL of water, 10 mL of brine and dried (Na₂SO₄). After filtration and concentration, the crude residue was purified by chromatography on silica gel. The desired product (R_f=0.3, 60% EtOAc/hexane) was isolated as colorless oil (32 mg, 11% yield from 14). ¹H-NMR (CDCl₃) δ 7.30-7.17 (m, 5H), 5.68 (m, 2H), 5.09 (septet, J = 6.4 Hz, 1H), 4.32-3.95 (m, 6H), 3.68 (m, 1H), 2.75 (m, 2H), 2.36 (m, 3H), 2.20 (m, 3H), 1.83-1.35 (m, 8H), 1.24 (d, J = 6.6 Hz, 6H); ¹³C-NMR (CDCl₃) δ 170.26, 142.08, 131.78, 128.40, 128.35, 126.77, 125.81, 75.73, 70.55, 68.81, 67.66, 66.66, 61.19, 54.17, 51.09, 44.43, 39.09, 34.81, 32.20, 30.19, 29.73, 21.79.

L: (5Z)-(11R, 15R)-11, 15-Dihydroxy-3-oxa-17-phenyl-18,19,20-trinor-5-prostenoic Acid Isopropyl Ester (II):

To a solution of the iodoester 15 (32 mg, 0.05 mmol) and AIBN (10 mg) in 1.0 mL of anhydrous toluene, Bu₃SnH (0.03 g, 0.10 mmol) was added. The resulting mixture was heated at reflux for 3 h. The reaction mixture was cooled to room temperature, the solvent was evaporated and the residue was purified by chromatography on silica gel. Compound II (R_f=0.23, 60% EtOAc/hexane) was isolated as colorless oil (22 mg, 95% yield). ¹H-NMR (CDCl₃) δ 7.29-7.17 (m, 5H), 5.72 (m, 2H), 5.10 (septet, J = 6.4 Hz, 1H), 4.00 (m, 4H), 3.92 (m, 1H), 3.69 (m, 1H), 2.75 (m, 2H), 2.22 (m, 1H), 2.08 (m, 1H), 1.98 - 1.31 (m, 14H), 1.27 (d, J = 6.6 Hz, 6H); ¹³C-NMR (CDCl₃) δ 170.06, 142.14, 134.43, 128.38, 126.53, 125.79, 79.10, 72.00, 71.34, 68.48, 67.17, 53.30, 44.09, 39.02, 38.19, 35.36, 34.20, 32.14, 29.05, 28.93, 21.79; HRMS (MH)⁺ calcd. for C₂₅H₃₉O₅, 419.27975, found 419.27920.

EXAMPLE 2: SYNTHESIS OF 9-DEOXY-17-PHENYL PGF_{2α}

A: (5Z, 13E)-(9S, 11R, 15S)-11, 15-Bis-(tetrahydropyran-2-yloxy)-9-hydroxy-17-phenyl-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (17):

5 A solution of the lactone 6 (3.4 g, 7.08 mmol) (see Example 1) in dry THF (50 mL) was cooled to -78 °C and to it was added DIBAL-H (6.0 mL, 1.5 M in toluene). The mixture was stirred at -78 °C for 15 min and then quenched by the addition of 10 mL of methanol. The resulting mixture was warmed to room temperature, 50 mL of a saturated solution of potassium sodium tartrate was added and stirred for an additional hour. The layers were separated and the aqueous layer was washed with 2 X 20 mL of EtOAc. Combined organic layers
10 were dried (Na_2SO_4), filtered and concentrated to afford 3.2 g of lactol 16 (quantitative yield). The crude product mixture was used in the next reaction without further purification.

A suspension of (4-carboxybutyl)triphenylphosphonium bromide (13.3 g,

30.0 mmol) in THF (40 mL) was cooled to 0 °C and was treated with a solution of potassium tert-butoxide in THF (60 mL, 1.0 M in THF). The resulting mixture was stirred for 30 min at which time a solution of the lactol 16 (3.2 g, 6.6 mmol) in THF (20 mL) was added. The reaction was allowed to warm to room temperature and stirred at that temperature for 12 h. The reaction mixture was poured into a separatory funnel containing 50 mL each of EtOAc and sat. NH₄Cl. The layers were separated and the aqueous layer was washed with 2 X 20 mL of EtOAc. Combined organic layers were dried (Na₂SO₄), filtered and concentrated. The crude product mixture was dissolved in CH₂Cl₂, cooled to 0 °C and then treated with excess ethereal diazomethane. Solvent was removed and the crude ester was applied to a silica gel column for chromatography. The ester 17 (R_f=0.3, EtOAc/hexane 1:2) was isolated as a slightly yellow oil (2.74 g, 80% yield from 6).

B: (5Z, 13E)-(9S, 11R, 15S)-11,15-Bis-(tetrahydropyran-2-yloxy)-17-phenyl-9-p-toluenesulfonyloxy-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (18):

A mixture consisting of the ester 17 (2.74 g, 4.8 mmol) and TsCl (3.66 g, 19.2 mmol) in anhydrous pyridine (40 mL) was stirred at 0 °C for 4 h and then at room temperature for 48 h. The reaction mixture was then poured into 200 mL of ice-cold water and extracted with 4 X 30 mL of benzene. The combined organic layers were washed with 2 X 50 mL of a 1M solution of NaHSO₄ and brine. The organic phase was dried (Na₂SO₄), filtered and concentrated. The crude product was purified by chromatography on silica gel. The tosylate 18 was isolated as a slightly yellow oil (2.23 g, 65% yield).

C: (5Z, 13E)-(9S, 11R, 15S)-11, 15-Bis-acetoxy-17-phenyl-9-p-toluenesulfonyloxy-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (19):

A solution of ester 18 (2.23 g, 3.08 mmol) in dry methanol (40 mL) was treated with boron trifluoride etherate (2 drops) for 30 min at room temperature. At which time triethylamine (0.5 mL) was added, the solvent was removed and the residue was taken up in 30 mL of benzene. To this solution 100 mg of 4-dimethylaminopyridine, 5.0 mL of triethylamine and 3.0 mL of acetic anhydride were added and the resulting mixture was stirred at room temperature for 15 min.

The reaction was then quenched by pouring it into a biphasic mixture of EtOAc and water. The layers were separated and aqueous layer was extracted with 3 X 20 mL of EtOAc. The combined organic layers were washed with sat. NaHCO₃, and brine, dried over Na₂SO₄, filtered and concentrated. The bis-acetate 19 (1.25 g, 64% yield) was isolated as a colorless oil after chromatography of the crude on silica (R_f=0.4, EtOAc/hexane 1:2).

D: (5Z, 13E)-(9R, 11R, 15S)-11, 15-Bis-acetoxy-9-chloro-17-phenyl-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (20):

A mixture of tosylate 19 (1.25, 1.97 mmol) and LiCl (1.7 g, 40 mmol) in 40 mL of acetone was stirred at room temperature for 3 days. The solvent was removed and the crude residue was partitioned between 50 mL each of EtOAc and water. The organic layer was washed with brine, dried (Na₂SO₄) and concentrated. The crude residue was purified by chromatography on silica gel to afford 20 (570 mg, 52% yield) as a yellow oil.

E: (5Z, 13E)-(11R, 15S)-11, 15-Bis-acetoxy-17-phenyl-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (21):

A solution containing 20 (570 mg, 1.07 mmol), Bu₃SnH (1.5 mL, 5.7 mmol) and a trace amount of AIBN in 10 mL of dry benzene was heated at 50 °C under an atmosphere of N₂ for 3 h. The solvent was then removed and the residue was dissolved in 150 mL of CH₃CN and washed with 3 x 50 mL of hexanes. The combined hexane layers were washed with 2 X 20 mL of CH₃CN. The acetonitrile layers were combined and evaporated and the residue was applied to a column of silica gel for chromatographic purification. Ester 21 (455 mg, quantitative yield) was isolated as a colorless oil.


F: (5Z, 13E)-(11R, 15S)-11, 15-Dihydroxy-17-phenyl-18,19,20-trinor-5,13-prostadienoic Acid Methyl Ester (22):

A mixture of 22 (455 mg, 0.99 mmol) and K₂CO₃ (200 mg) in 10 mL of methanol was stirred at room temperature for 2 h. Water (10 mL) was added and the pH of the reaction mixture was adjusted to 2-3 with 1N HCl solution. Solvent

was removed and the residue was partitioned between EtOAc/water (20 mL each). The aqueous layer was extracted with 2 X 20 mL of EtOAc. The organic layers were combined and dried (Na_2SO_4). Filtration and solvent removal gave crude **22** as a yellow oil, which was purified by chromatography on silica gel ($R_f=0.14$, 1:1 EtOAc/hexane) to afford 160 mg (43% yield) of **22** as a colorless liquid.

G: (5Z, 13E)-(11R, 15S)-11, 15-Dihydroxy-17-phenyl-18,19,20-trinor-5,13-prostadienoic Acid (III):

A solution of ester **22** (160 mg, 0.41 mmol) in 5 mL of methanol was treated with 2.0 mL of 1N NaOH for a period of 2 h at room temperature. The mixture was then acidified to pH 2 with 1N HCl and extracted with EtOAc (4 X 20 mL). Combined organic layers were washed with brine and dried (Na_2SO_4). The crude product, after filtration and solvent removal, was purified by passage through a short pad of silica gel using a mixture of hexane/acetone/water (4:3:1) as the eluent. Compound **III** (107 mg, 70% yield) was obtained as a colorless viscous liquid. $^1\text{H-NMR}$ (CDCl_3) δ 7.29-7.15 (m, 5H), 5.56-5.20 (broad m, 7H), 4.10 (q, $J = 6.5$ Hz, 1H), 3.81 (q, $J = 7.7$ Hz, 1H), 2.66 (m, 2H), 2.29 (m, 2H), 2.17-1.24 (broad, 13H); $^{13}\text{C-NMR}$ (CDCl_3) δ 177.80, 141.85, 134.78, 133.49, 129.39, 128.96, 128.41, 128.37, 125.82, 78.05, 72.34, 57.73, 43.07, 38.51, 33.05, 32.33, 31.81, 31.70, 27.60, 26.36, 24.50.

EXAMPLE 3: SYNTHESIS OF 9-DEOXYCLOPROSTENOL ISOPROPYL ESTER

A: Ethyl (3-chlorophenoxy)acetate (24):

To a mixture of 320 mL of acetone, 75 g (450 mmol) of ethyl bromoacetate, and 40.0 g (310 mmol) of 3-chlorophenol (23) was added 69.8 g (505 mmol) of potassium carbonate. The mixture was mechanically stirred and heated to reflux
5 for 4h, and after cooling to room temperature, was poured into 350 mL of ethyl acetate. To this was then cautiously added 400 mL of 1 M HCl, taking care to avoid excess foaming. The layers were separated, and the aqueous layer was extracted with 3 X 200 mL portions of ethyl acetate. The combined organic layers were dried over MgSO_4 and concentrated. The residue was melted in 500 mL of
10 hot hexane and allowed to re-solidify. Filtration of the solution afforded 58 g (87%) of 24 as a flaky white solid, m.p. = 39-40 °C. ^1H NMP. δ 7.20-7.08 (m, 1H),

6.95-6.82 (m, 2H), 6.75-6.70 (m, 1H), 4.53 (s, 2H), 4.21 (q, $J = 7.2$ Hz, 2H), 1.23 (t, $J = 7.2$ Hz, 3H).

B: Dimethyl [3-(3-chlorophenoxy)-2-oxoprop-1-yl]phosphonate (25):

To 20.6 g (166 mmol, 238 mol %) of dimethyl methylphosphonate in 110 mL of THF at -78°C was added dropwise 65 mL (162 mmol, 232 mol %) of a 2.5 M solution of *n*-BuLi in hexanes. After the addition was complete, the mixture stirred for an additional 1h, at which time 15.0 g (69.9 mmol) of aryloxyester **24** was added dropwise as a solution in 40 mL of THF. The reaction was stirred for 1h and then quenched by the addition of 100 mL of saturated NH_4Cl . The mixture was poured into 200 mL of a 1:1 mixture of saturated brine: ethyl acetate, the layers were separated, and the aqueous layer was extracted with 2 X 100 mL portions of ethyl acetate. The combined organic layers were dried over MgSO_4 and concentrated, and the residue was dried on a pump to afford 20.5 g (100%) of **25** as a viscous oil. ^1H NMR δ 7.22 (t, $J = 8.1$ Hz, 1H), 7.05-6.90 (m, 2H), 6.85-6.78 (m, 1H), 4.72 (s, 2H), 3.84 (s, 3H), 3.78 (s, 3H), 3.27 (d, $J = 22.8$ Hz, 2H).

C: (3a*R*, 4*R*, 5*R*, 6a*S*)-5-(Benzoyloxy)-4-[(*E*)-4-(3-chlorophenoxy)-3-oxo-1-butenyl]-hexahydro-2*H*-cyclopenta[b]furan-2-one (26):

To a mixture of 20.5 g (70.0 mmol) of phosphonate **25**, 2.6 g (62 mmol) of LiCl, and 200 mL of THF at 0°C was added 6.10 g (60.4 mmol) of NEt_3 . The mixture became thick as a precipitate formed. At that time 14.0 g (51.1 mmol) of aldehyde **1** dissolved in 50 mL of CH_2Cl_2 was added dropwise. After 1h the reaction was poured into 200 mL of a 1:1 mixture of saturated NH_4Cl :ethyl acetate, the layers were separated, and the aqueous layer was extracted with 2 X 100 mL portions of ethyl acetate. The combined organic layers were dried over MgSO_4 and concentrated, and the residue was flash chromatographed on a 28 cm tall X 51 mm diameter silica gel column eluting with 3:2 v/v ethyl acetate:hexanes to afford 16.2 g (72%) of **26** as a white crystalline solid, m.p. = 101.0 - 102.0°C . ^1H NMR δ 8.0-7.9 (m, 2H), 7.62-7.52 (m, 1H), 7.50-7.38 (m, 2H), 7.18 (t, $J = 8.2$ Hz, 1H), 7.0-6.82 (m, 3H), 6.75-6.70 (m, 1H), 6.54 (d, $J = 151.1$ Hz, 1H), 5.32 (q, $J = 6.2$ Hz, 1H), 5.08 (m, 1H), 4.66 (s, 2H), 3.0-2.8 (m, 3H), 2.7-2.2 (m, 3H).

D: (3aR, 4R, 5R, 6aS)-5-(Benzoyloxy)-4-[(E)-(3R)-4-(3-chlorophenoxy)-3-hydroxy-1-butenyl]-hexahydro-2H-cyclopenta[b]furan-2-one (27):

To a solution of 9.70 g (22.0 mmol) of enone 26 in 60 mL of THF at -23 °C was added dropwise a solution of 11.1 g (34.6 mmol) of (-)-DIPCl in 30 mL of THF. After 4h, the reaction was quenched at -23 °C by the dropwise addition of 5 mL of methanol, and was warmed to room temperature. The mixture was then poured into 200 mL of a 2:1 mixture of ethyl acetate: saturated NH₄Cl, the layers were separated, and the aqueous phase was extracted with 2 X 100 mL portions of ethyl acetate. The combined organic layers were dried over MgSO₄, concentrated, and the residue was flash chromatographed on a 33 cm tall X 76 mm diameter silica gel column eluting with 3:2 v/v ethyl acetate:hexanes to afford 4.7 g (48%) of 27 as a white solid, m. p. 101.0-102.5 °C. ¹H NMR δ 8.05-7.95 (m, 2H), 7.62-7.40 (m, 3H), 7.18 (t, J = 8.0 Hz, 1H), 7.0-6.92 (m, 1H), 6.85 (t, J = 2.1 Hz, 1H), 6.77-6.70 (m, 1H), 5.85 (d of d, J = 6.2, 15.5 Hz, 1H), 5.72 (d of d, J = 4.5, 15.5 Hz, 1H), 5.30 (q, J = 5.8 Hz, 1H), 5.12-5.04 (m, 1H), 4.58-4.48 (m, 1H), 3.92 (d of d, J = 3.5, 9.3 Hz, 1H), 3.80 (d of d, J = 7.3, 9.4 Hz, 1H), 2.9-2.2 (m, 8H).

E: (3aR, 4R, 5R, 6aS)-4-[(E)-(3R)-4-(3-Chlorophenoxy)-3-(tetrahydropyran-2-yloxy)-1-butenyl]-hexahydro-5-(tetrahydropyran-2-yloxy)-2H-cyclopenta[b]furan-2-one (29):

To a mixture of 5.1 g (11.5 mmol) of 27 and 200 mL of methanol was added 1.7 g (12 mmol) of K₂CO₃. After 1h the mixture was poured into 100 mL of 0.5 N HCl and extracted with 3 X 100 mL portions of ethyl acetate. The combined organic layers were washed successively with 2 X 100 mL portions of water and 2 X 100 mL portions of saturated brine. The organic layer was dried over MgSO₄, filtered, and concentrated to afford 4.85 g (>100%) of crude diol 28, which was used in the next step without further purification.

To a mixture of 4.85 g of crude **28** (11.5 mmol = 3.9 g of **28** present in the sample if previous step gave 100% yield) and 2.4 g (28 mmol) of 3,4-dihydro-2-H-pyran in 75 mL of CH₂Cl₂ at 0 °C was added 370 mg (1.9 mmol) of *p*-TsOH. After stirring for 45 min, the reaction was poured into 40 mL of saturated aqueous NaHCO₃, the layers were separated, and the aqueous layer was extracted with 2 X 40 mL portions of CH₂Cl₂. The combined organic layers were dried over MgSO₄, filtered and concentrated. The residue was flash chromatographed on a 20 cm tall x 41 mm diameter silica gel column, eluting with 40% ethyl acetate in hexanes, to afford 6.0 g (100%) of **29** as an oil. ¹H NMR (CDCl₃) δ (characteristic peaks only) 7.25-7.14 (m, 1H), 6.95-6.87 (m, 2H), 6.83-6.72 (m, 1H), 5.8-5.4 (m, 4H), 5.1-4.8 (m, 2H).

F: (5Z, 13E)-(9S, 11R, 15R)-11,15-Bis(tetrahydropyran-2-yloxy)16-(3-chlorophenoxy)-9-hydroxy-17,18,19,20-tetranor-5,13-prostadienoic Acid Isopropyl Ester (32):

To a solution of 5.8 g (11.4 mmol) of lactone **29** in 55 mL of THF at -78 °C was added dropwise 10 mL (15 mmol) of a 1.5 M solution of DIBAL in toluene. After 1h 10 mL of methanol was added dropwise, and the mixture was stirred for 10 min at -78 °C before being warmed to room temperature. The mixture was poured into 100 mL of a 1:1 solution of saturated aqueous potassium sodium tartrate:ethyl acetate and was stirred until the emulsion broke. After separating the layers, the aqueous layer was extracted with 2 X 40 mL portions of ethyl acetate, the combined organic layers were dried over MgSO₄, filtered, and concentrated, and the residue was flash chromatographed on a 22 cm tall X 41 mm diameter silica gel column eluting with 3:2 ethyl acetate:hexane to afford 4.4 g (76%) of lactol **30**, which was used immediately in the next step.

To 12.1 g (27.3 mmol) of phosphonium salt **31** in 100 mL of THF at 0 °C was added dropwise 50.0 mL of a 1 M solution in THF of potassium *t*-butoxide. After 30 min, a solution of 4.4 g (8.6 mmol) of lactol **30** in 20 mL of THF was added dropwise, and the mixture was stirred at room temperature overnight. The mixture was then poured into 150 mL of a 1:1 mixture of ethyl acetate:saturated aqueous NH₄Cl, the layers were separated, and the aqueous layer was extracted with 2 X 100 mL portions of ethyl acetate. The combined organic layers were

dried over MgSO_4 , filtered, and concentrated, and the residue was dissolved in 80 mL of acetone. To this was added successively 6.5 g (43 mmol) of DBU and 7.3 g (43 mmol) of isopropyl iodide. After stirring overnight, the reaction was poured into 100 mL of a 1:1 mixture of ethyl acetate:saturated aqueous NH_4Cl , the layers were separated, and the aqueous layer was extracted with 2 X 100 mL portions of ethyl acetate. The combined organic layers were dried over MgSO_4 , filtered, and concentrated, and the residue was flash chromatographed on a 27 cm tall X 41 mm diameter silica gel column eluting with 40% ethyl acetate in hexane to afford 2.92 g (53% from lactone 29) of ester 32.

10 G: (5Z, 13E)-(11R, 15R)-11, 15-Bis(tetrahydropyran-2-yloxy)-16-(3-chlorophenoxy)-17,18,19,20-tetranor-5, 13-prostadienol (33):

To a solution of ester 32 (1.34 g, 2.11 mmol) in pyridine (18 mL) at 0 °C was added dropwise mesyl chloride (590 mg, 5.2 mmol). After stirring overnight (18h) at 0 °C, the reaction was poured into a mixture of 50 mL of sat. CuSO_4 /75 mL of EtOAc. The resulting suspension was filtered through Celite, the layers were separated, the aqueous layer was extracted with EtOAc (2 X 50 mL). The combined organic layers were dried (MgSO_4), filtered and concentrated and the residue was purified by chromatography on silica gel to afford the intermediate 9 α -mesylate (1.32 g, 88% yield).

20 This mesylate was dissolved in 16 mL of THF, the solution was cooled to 0 °C and to it LiEt_3BH (11.0 mL, 1.0 M in THF) was added dropwise. The reaction was stirred at 0 °C for 1h, and then at room temperature for 18h. At this time 60 mL of sat. NH_4Cl solution was added and the resulting mixture was extracted with EtOAc (3 X 50 mL). The combined organic extracts were dried (MgSO_4), filtered and concentrated. The crude product mixture was purified by chromatography on silica gel (R_f =0.5, 40% EtOAc/hexane) to afford 33 (726 mg, 69% yield).


H: (5Z, 13E)-(11R, 15R)-11, 15-Bis(tetrahydropyran-2-yloxy)-16-(3-chlorophenoxy)-17,18,19,20-tetranor-5, 13-prostadienoic Acid Isopropyl Ester (34):

A mixture of 33 (190 mg, 0.33 mmol), PDC (650 mg, 1.73 mmol) and DMF (4.5 mL) was stirred at room temperature for 24h. The reaction was then
5 partitioned between 25 mL of EtOAc and 20 mL of water. The layers were separated and the aqueous layer was extracted with 2 X 25 mL of EtOAc. The combined organic extracts were dried (Na_2SO_4), filtered and concentrated. The residue was dissolved in acetone (15 mL) and to it DBU (110 mg, 0.73 mmol) and isopropyl iodide (120 mg, 0.70 mmol) were added. The resulting mixture was
10 stirred for 18h at room temperature and was then partitioned between EtOAc (25 mL) and sat. NH_4Cl (15 mL). The layers were separated and the aqueous layer was extracted with 2 X 25 mL of EtOAc. The organic extracts were combined and dried (MgSO_4), filtered and concentrated. The residue was purified by chromatography on silica gel ($R_f=0.6$, 30% EtOAc/hexane) to yield 34 (115 mg,
15 56%).

I: (5Z, 13E)-(11R, 15R)-16-(3-Chlorophenoxy)-11, 15-dihydroxy-17,18,19,20-tetranor-5, 13-prostadienoic Acid Isopropyl Ester (IV):

A solution of 34 (79 mg, 0.13 mmol), water (1.0 mL), isopropyl alcohol (10 mL) and 12 N HCl (800 μL) was stirred at room temperature for 1h. At this time
20 12 mL of a sat. NaHCO_3 solution was added dropwise and the resulting mixture was extracted with EtOAc (3 X 25 mL). The combined organic extracts were dried (MgSO_4), filtered and concentrated and the residue was applied to a column of silica gel for chromatographic purification ($R_f=0.5$, 60% EtOAc/hexane). Compound IV (48 mg, 82% yield), was isolated as a colorless oil. ^{13}C NMR
25 (CDCl_3) δ 173.20, 159.24, 136.27, 134.88, 130.24, 129.98, 129.59, 128.62, 121.30, 115.07, 113.07, 77.87, 71.91, 70.95, 67.46, 57.90, 42.87, 34.03, 32.23, 31.57, 27.59, 26.61, 24.85, 21.81.

EXAMPLE 4: SYNTHESIS OF COMPOUND VI



A: [3aR, 4R(1E, 3R), 5R, 6aS]-4-[3-hydroxy-3-(2-indanyl)propyl]-5-hydroxy-hexahydro-2H-cyclopenta[b]furan-2-one (36)

A solution of olefin 35 (0.7 g, 2.2 mmol) (synthesis described in: *J. Med. Chem.* 1983, 26, 328) in 10 mL of a 1:1 v:v mixture of methanol:ethyl acetate was hydrogenated in the presence of 10% Pd/C (50 mg) at 40 psi in a Parr hydrogenation apparatus for 1h. The mixture was filtered through Celite and concentrated to afford 36, which was used in the next step without further purification.

B: [3aR, 4R(1E, 3R), 5R, 6aS]-4-[3-(2-indanyl)-3-(tetrahydropyran-2-yloxy)propyl]-5-(tetrahydropyran-2-yloxy)-hexahydro-2H-cyclopenta[b]furan-2-one (37)

Compound 36 from above was dissolved in CH₂Cl₂ (30 mL) and the mixture was cooled to 0 °C. 3,4-dihydro-2H-pyran was added (0.42 g, 5.0 mmol), followed by *P*-toluenesulfonic acid monohydrate (50 mg, 0.2 mmol). The solution was stirred at room temperature for 2h, poured into saturated aqueous NaHCO₃, and extracted with CH₂Cl₂. The solution was dried over MgSO₄, filtered, and concentrated, and the residue was chromatographed on silica gel to afford 0.4 g (36%) of 37 as a viscous oil. ¹H NMR (CDCl₃) δ 7.2 (m, 4 H), 5.0 (m, 1 H), 4.7 (m, 2 H).

C: (5Z)-(9S, 11R, 15R)-11,15-Bis(tetrahydropyran-2-yloxy)-9-hydroxy-15-(2-indanyl)-16,17,18,19,20-pentanol-5-prostenoic acid methyl ester (39)

To a -78 °C solution of lactone 37 (0.4 g, 0.8 mmol) in toluene (10 mL) was added a 1.5 M solution of DIBAL-H in hexane (1 mL, 1 mmol). After stirring for 2 h at 0 °C, isopropanol (0.2 mL) was added, the mixture was poured into a solution of sodium potassium tartrate, extracted with ethyl acetate (2 x 50 mL), dried (MgSO₄), and concentrated to afford 0.21 g (52%) of crude lactol 38.

To a solution of (4-carboxybutyl)triphenylphosphonium bromide (0.13 g, 0.3 mmol) in DMSO (6 mL) was added a DMSO solution of sodium methylsulfinylmethide (0.6 mmol, 0.2 M in DMSO). To the mixture was added dropwise a solution of lactol 38 (0.15 g, 0.3 mmol) in DMSO (3 mL). The solution was stirred for 16 h at 50 °C, cooled to room temperature, and quenched by the addition of 10% aqueous citric acid to pH 5.5. The mixture was extracted with ethyl acetate, dried (MgSO₄), filtered, and concentrated. The residue was dissolved in acetone (5 mL) and DBU was added (0.15 g, 1.0 mmol), followed by iodomethane (0.14 g, 1.0 mmol). The solution was stirred for 30 min, poured into water,

extracted with ether (2 X 50 mL), dried (MgSO₄), filtered, and concentrated, and the residue was chromatographed on silica gel to eluting with 7:3 hexane:ethyl acetate to furnish 0.2 g (98%) of **39**. ¹H NMR (CDCl₃) δ 7.13 (m, 4H), 5.4 (m, 2H), 4.7 (m, 2H), 4.1-3.8 (m, 4H), 3.7 (s, 3H), 3.1-2.7 (m, 4H), 2.3 (t, 3H), 2.1 (m, 2H), 1.9-1.2 (m, 29H).

5 **D: (5Z)-(11R, 15R)-11,15-Bis(tetrahydropyran-2-yloxy)-15-(2-indanyl)-16,17,18,19,20-pentanol-5-prostenol (40)**

A solution of **39** (0.2 g, 0.4 mmol) in pyridine (20 mL) at 0 °C was treated with methanesulfonyl chloride (0.17 g, 1.5 mmol). The mixture was stirred at 0°C for 2 h and at room temperature for 1.5 h. The solution was poured into saturated aqueous NH₄Cl and
10 extracted with ether (2 x 50 mL). The combined organic extracts were washed with a saturated aqueous solution of CuSO₄ (3 x 50 mL), dried (MgSO₄), filtered, and concentrated, and the residue was passed through a short column of silica gel eluting with 1:1 hexane:ethyl acetate to afford 0.25 g (100%) of the 9α-mesylate.

To a 0 °C solution of the mesylate (0.25 g, 0.4 mmol) in THF (30 mL) was added
15 a 1 M solution of LiEt₃BH in THF (9 mL, 9 mmol). The reaction was stirred at room temperature for 3 d, was added to a saturated aqueous solution of NH₄Cl (50 mL), extracted with ether (50 mL), dried (MgSO₄), filtered, and concentrated to afford **40** (0.2 g, 68%).

E: (5Z)-(11R, 15R)-11,15-Bis(tetrahydropyran-2-yloxy)-15-(2-indanyl)-16,17,18,19,20-pentanol-5-prostenoic acid isopropyl ester (42)

20 A solution of **40** (0.2 g, 0.3 mmol), DMF (20 mL), and pyridinium dichromate (1.2 g, 3.2 mmol) was stirred for 16 h. The mixture was poured into saturated aqueous citric acid (50 mL), extracted with ethyl acetate (2 X 100 mL), dried (MgSO₄), filtered, and concentrated to afford 0.2 g of crude acid **41**.

A solution of crude acid **41** (0.2 g, 0.3 mmol) in acetone (30 mL) was treated
25 sequentially with DBU (0.5 g, 3 mmol) and 2-iodopropane (0.8 g, 5 mmol). After stirring for 16 h, the mixture was poured into water, extracted with ethyl acetate (50 mL), dried (MgSO₄), filtered, and concentrated to afford **42** (66 mg, 37%).

E: (5Z)-(11R, 15R)-11,15-dihydroxy-15-(2-indanyl)-16,17,18,19,20-pentanol-5-prostenoic acid isopropyl ester (VI)

A solution of 42 (66 mg, 0.11 mmol) in 7 mL of a 4:2:1 v:v:v mixture of acetic acid, THF, and water was heated at 50 °C for 30 min and then stirred at room temperature for 16 h. The reaction was neutralized with NaHCO₃, 100 mL of water was added, the mixture was extracted with ethyl acetate (2 x 50 mL), the combined organic extracts were dried (MgSO₄), filtered, and concentrated, and the residue was chromatographed on silica gel eluting with 7:3 ethyl acetate:hexane to afford VI (18 mg, 41%) as a clear colorless oil. ¹H NMR (CDCl₃) δ 7.3-7.1 (m, 4H), 5.4 (m, 2H), 5.0 (septet, J = 6.3 Hz, 1H), 3.9 (m, 1H), 3.7 (m, 1H), 3.1 (m, 1H), 2.9 (m, 1H), 2.8 (m, 1H), 2.6 (m, 1H), 2.4 (m, 2H), 2.1 (m, 2H), 1.8-1.4 (m, 13H), 1.2 (d, J = 6.3 Hz, 6H). ¹³C NMR (CDCl₃) δ 173.3, 143.1, 142.9, 129.4, 129.3, 126.2, 124.5, 124.3, 79.2, 75.5, 67.5, 53.5, 46.1, 44.8, 35.8, 35.4, 34.3, 34.1, 33.9, 32.7, 29.3, 29.0, 26.7, 25.0, 21.8.

The compounds of formula (I) are useful in lowering intraocular pressure and thus are useful in the treatment of glaucoma. The preferred route of administration is topical. The dosage range for topical administration is generally between about 0.001 and about 1000 micrograms per eye ($\mu\text{g}/\text{eye}$) and is
5 preferably between about 0.01 and about 100 ($\mu\text{g}/\text{eye}$) and most preferably between about 0.1 and about 20 $\mu\text{g}/\text{eye}$. The compounds of the present invention may be administered as solutions, suspensions, or emulsions (dispersions) in a suitable ophthalmic vehicle.

In forming compositions for topical administration, the compounds of the
10 present invention are generally formulated as between about 0.000003 and about 1 percent by weight (wt%) solutions in water at a pH between about 4.5 and about 8.0. It is preferable to use concentrations between about 0.00003 and about 0.3 wt% and, most preferably between about 0.002 and about 0.1 wt%. While the precise regimen is left to the discretion of the clinician, it is recommended that the
15 resulting solution be topically applied by placing one drop in each eye one or two times a day.

Other ingredients which may be desirable to use in the ophthalmic preparations of the present invention include preservatives, co-solvents and viscosity building agents.

20 **Antimicrobial Preservatives:**

Ophthalmic products are typically packaged in multidose form, which generally require the addition of preservatives to prevent microbial contamination during use. Suitable preservatives include: benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben, propyl paraben, phenylethyl alcohol, edetate
25 disodium, sorbic acid, ONAMER M® (polyquaternium-1), or other agents known to those skilled in the art. Such preservatives are typically employed at a concentration between about 0.001 and about 1.0 wt%.

Prostaglandins, and prostaglandin derivatives, typically have limited solubility in water and therefore may require a surfactant or other appropriate co-solvent in the composition. Such co-solvents include: Polysorbate 20, 60 and 80; Pluronic F-68, F-84 and P-103; Tyloxapol; Cremophor® EL; sodium dodecyl sulfate; glycerol; PEG 400; propylene glycol; cyclodextrins; or other agents known to those skilled in the art. Such co-solvents are typically employed at a concentration between about 0.01 and about 2 wt%.

Viscosity Agents:

Viscosity greater than that of simple aqueous solutions may be desirable to increase ocular absorption of the active compound, to decrease variability in dispensing the formulations, to decrease physical separation of components of a suspension or emulsion of formulation and/or otherwise to improve the ophthalmic formulation. Such viscosity building agents include: polyvinyl alcohol; polyvinyl pyrrolidone; cellulosic polymers, such as methyl cellulose, hydroxy propyl methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose, hydroxy propyl cellulose; carboxy vinyl polymers, such as carbomer 910, carbomer 940, carbomer 934P and carbomer 1342; or other agents known to those skilled in the art. Such agents are typically used at a concentration between about 0.01 and about 2 wt%.

EXAMPLE 5


The following Formulations A-C are representative pharmaceutical compositions of the invention for topical use in the treatment of glaucoma and for lowering of intraocular pressure. Each of Formulations A-C may be formulated in accordance with procedures known to those skilled in the art.

INGREDIENT	FORMULATION (wt%)		
	A	B	C
Compound II	0.01	---	---
Compound IV	---	---	0.003
Compound V	---	0.01	---
5 Monobasic Sodium Phosphate	0.05	0.05	0.05
Dibasic Sodium Phosphate (anhydrous)	0.15	0.15	0.15
Sodium Chloride	0.75	0.75	0.75
Disodium EDTA	0.01	0.05	0.05
10 Cremophor® EL	---	0.01	---
Hydroxypropyl- β -cyclodextrin	---	---	---
Tyloxapol	---	---	---
Benzalkonium Chloride	0.02	0.01	0.01
Polysorbate 80	0.15	---	---
15 HCl and/or NaOH	q.s. to pH 7.3-7.4	q.s. to pH 7.3-7.4	q.s. to pH 7.3-7.4
Purified Water	q.s. to 100%	q.s. to 100%	q.s. to 100%

The invention has been described by reference to certain preferred
 embodiments; however, it should be understood that it may be embodied in other
 specific forms or variations thereof without departing from its spirit or essential
 20 characteristics. The embodiments described above are therefore considered to be
 illustrative in all respects and not restrictive, the scope of the invention being
 indicated by the appended claims rather than by the foregoing description.

What is Claimed is:

1. A method of treating glaucoma and ocular hypertension which comprises topically administering to the affected eye a therapeutically effective amount of a compound of formula:



wherein:

$Y = C(O)NR_1R_2, CH_2OR_3, CH_2NR_1R_2, CO_2R_1, CO_2M$ where M is a cationic salt moiety;

R_1, R_2 (same or different) = H, C_1-C_6 alkyl or alkenyl, or C_3-C_6 cycloalkyl;

R, R_3 (same or different) = $C(O)R_4, H$;

$R_4 = C_1-C_6$ alkyl or alkenyl, or C_3-C_6 cycloalkyl;

$X = O, S(O)_n, CH_2$;


$n = 0, 1, \text{ or } 2$;

$A = CH_2CH_2, \text{ cis or trans } CH=CH, \text{ or } C\equiv C$;

$Z = CH_2CH_2, \text{ trans } CH=CH, \text{ or } C\equiv C$;

$W = (CH_2)_m \text{ Aryl}, (CH_2)_m \text{ O Aryl}$ where $m = 1-6$ and Aryl = phenyl, optionally substituted with halogen, hydroxy, alkoxy, haloalkyl, amino, or acylamino; or

$W =$




where $V = H, \text{ alkyl, halogen, hydroxy, alkoxy, acryloxy, haloalkyl, amino,}$

acylamino, and $L = CH_2, O, S(O)_m, CH_2CH_2, CH_2O, NR, CH=N, CH_2S(O)_m,$
 $CH=CH, CH_2NR$ where $m = 0-2$ and R is as defined above.

2. The method of claim 1, wherein: $Y = CO_2R_1$; $R_1 = CH(CH_3)CH_3$, or H ; $X = CH_2$; $A = cis\ CH=CH$; $R = H$; $Z = CH_2CH_2$, or $trans\ CH=CH$; $W = (CH_2)_m\ Aryl$, or
5 $(CH_2)_m\ OAryl$ where $m = 1-3$, and $Aryl = phenyl$, optionally substituted with CF_3 ,
 Cl, F , or OMe ; or $W = W_1, W_2$, or W_3 .
3. The method of claim 1, wherein between about 0.001 and about 1000
micrograms of a compound of formula (I) is administered.
4. The method of claim 3, wherein between about 0.01 and about 100
10 micrograms of a compound of formula (I) is administered.
5. The method of claim 4, wherein between about 0.05 and about 50
micrograms of a compound of formula (I) is administered.

6. A topical ophthalmic composition for the treatment of glaucoma and ocular hypertension, said composition comprising an ophthalmically acceptable vehicle and a therapeutically effective amount of a compound of formula:



5 wherein:

$Y = C(O)NR_1R_2, CH_2OR_3, CH_2NR_1R_2, CO_2R_1, CO_2M$ where M is a cationic salt moiety;

R_1, R_2 (same or different) = H, C_1 - C_6 alkyl or alkenyl, or C_3 - C_6 cycloalkyl;

R, R_3 (same or different) = $C(O)R_4, H$;

10 $R_4 = C_1$ - C_6 alkyl or alkenyl, or C_3 - C_6 cycloalkyl;


$X = O, S(O)_n, CH_2$;

$n = 0, 1, \text{ or } 2$;

$A = CH_2CH_2, \text{ cis or trans } CH=CH, \text{ or } C\equiv C$;

$Z = CH_2CH_2, \text{ trans } CH=CH, \text{ or } C\equiv C$;

15 $W = (CH_2)_m \text{ Aryl}, (CH_2)_m \text{ OAryl}$ where $m = 1-6$ and Aryl = phenyl, optionally substituted with halogen, hydroxy, alkoxy, haloalkyl, amino, or acylamino; or $W =$



where $V = H, \text{ alkyl, halogen, hydroxy, alkoxy, acryloxy, haloalkyl, amino, acylamino, and } L = CH_2, O, S(O)_n, CH_2CH_2, CH_2O, NR, CH=N, CH_2S(O)_m, CH=CH, CH_2NR$ where $m = 0-2$ and R is as defined above.


7. The composition of claim 6, wherein: $Y = CO_2R_1$; $R_1 = CH(CH_3)CH_3$, or H; $X = CH_2$; $A = cis\ CH=CH$; $R = H$; $Z = CH_2CH_2$, or *trans* $CH=CH$; $W = (CH_2)_m\ Aryl$, or $(CH_2)_mOAr$ where $m = 1-3$, and $Aryl = phenyl$, optionally substituted with CF_3 , Cl, F, or OMe; or $W = W_1, W_2$, or W_3 .

8. The composition of claim 6, wherein between about 0.001 and about 1000 micrograms of a compound of formula (I) is administered.

9. The composition of claim 8, wherein between about 0.01 and about 100 micrograms of a compound of formula (I) is administered.

10. The composition of claim 9, wherein between about 0.05 and about 50 micrograms of a compound of formula (I) is administered.

11. A compound of formula:



wherein:

$Y = C(O)NR_1R_2$, CH_2OR_3 , or $CH_2NR_1R_2$;

R_1, R_2 (same or different) = H, C_1-C_6 alkyl or alkenyl, or C_3-C_6 cycloalkyl;

R, R_3 (same or different) = $C(O)R_4$, H;

$R_4 = C_1-C_6$ alkyl or alkenyl, or C_3-C_6 cycloalkyl;

$X = O, S(O)_n$, or CH_2 ;

$n = 0, 1$, or 2 ;

$A = CH_2CH_2$, *cis* or *trans* $CH=CH$, or $C\equiv C$;


$Z = CH_2CH_2$, *trans* $CH=CH$, or $C\equiv C$;

$W = (CH_2)_m\ Aryl$ or $(CH_2)_mOAr$; $m = 1-6$; and

$Aryl = phenyl$, optionally substituted with halogen, hydroxy, alkoxy, haloalkyl, amino, or acylamino.

12. The compound of claim 11, wherein: $Y = CH_2OR_3$ or $C(O)NR_1R_2$; R_1, R_2 (same or different) = H or Me; $R_3 = C(O)R_4$; $R_4 = C(CH_3)_3$; $X = CH_2$; $A = cis$ $CH=CH$; $R = H$; $Z = CH_2CH_2$ or $trans$ $CH=CH$; $W = (CH_2)_m$ Aryl or $(CH_2)_m$ OAryl; $m = 1-3$; and Aryl = phenyl, optionally substituted with CF_3 , Cl, F.

13. A compound of the formula:



wherein:

$Y = C(O)NR_1R_2, CH_2OR_3, CH_2NR_1R_2, CO_2R_1, CO_2M$ where M is a cationic salt moiety;

R_1, R_2 (same or different) = H, C_1-C_6 alkyl or alkenyl, or C_3-C_6 cycloalkyl;

R, R_3 (same or different) = $C(O)R_4, H$;

$R_4 = C_1-C_6$ alkyl or alkenyl, or C_3-C_6 cycloalkyl;



$X = O, S(O)_n, CH_2$;

$n = 0, 1, \text{ or } 2$;

$A = CH_2CH_2, cis$ or $trans$ $CH=CH$, or $C\equiv C$;

$Z = CH_2CH_2, trans$ $CH=CH$, or $C\equiv C$;

$W =$




$V = H, \text{ alkyl, halogen, hydroxy, alkoxy, acyloxy, haloalkyl, amino, acylamino,}$

and L = CH₂, O, S(O)_m, CH₂CH₂, CH₂O, NR, CH=N, CH₂S(O)_m, CH=CH, CH₂NR
 where m = 0-2 and R is as defined above.

14. The compound of claim 13 wherein Y = CO₂R₁; X = CH₂; A = *cis* CH=CH;
 R = H; R₁ = H or CH(CH₃)₂; Z = CH₂CH₂, or *trans* CH=CH; W = W₂; L = CH₂; and
 V = H.

15. The compound of claim 14 having the formula:



(VI).

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/12171

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K31/557 C07C405/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB,A,1 539 268 (ICI LTD) 31 January 1979 cited in the application	11
A	see the whole document ---	1-10, 12-15
A	WO,A,94 08587 (ALLERGAN INC) 28 April 1994 cited in the application see the whole document ---	1-15
A	WO,A,94 06432 (ALLERGAN INC) 31 March 1994 cited in the application see the whole document ---	1-15
A	EP,A,0 286 903 (UNIV COLUMBIA ; PHARMACIA AB (SE)) 19 October 1988 see the whole document ---	1-15
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- * "A" document defining the general state of the art which is not considered to be of particular relevance
- * "E" earlier document but published on or after the international filing date
- * "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- * "O" document referring to an oral disclosure, use, exhibition or other means
- * "P" document published prior to the international filing date but later than the priority date claimed

- * "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- * "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- * "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- * "A" document member of the same patent family

Date of the actual completion of the international search

19 January 1996

Date of mailing of the international search report

07.02.96

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+31-70) 340-3016

Authorized officer

Mair, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/12171

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>DATABASE WPI Section Ch, Week 9419 Derwent Publications Ltd., London, GB; Class B05, AN 94-156610 & JP,A,06 100 529 (ONO PHARM CO LTD) , 12 April 1994 see abstract</p> <p>---</p>	1-15
A	<p>EP,A,0 364 417 (PHARMACIA AB) 18 April 1990 cited in the application see the whole document</p> <p>-----</p>	1-15

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US95/12171

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claims 1-5 are directed to a method of treatment of the human/animal body the search has been carried out and based on the alleged effects of the compounds.
2. ☒ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
In view of the large number of compounds which are theoretically defined by the formula of claim 1 the search has had to be restricted on economic grounds to the exemplified compounds and the general concept of the application.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/12171

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
GB-A-1539268	31-01-79	DE-A- 2757834	06-07-78
		FR-A- 2375207	21-07-78
		JP-A- 53084943	26-07-78
WO-A-9408587	28-04-94	US-A- 5385945	31-01-95
		AU-B- 5409494	09-05-94
		CA-A- 2147502	28-04-94
		EP-A- 0665751	09-08-95
WO-A-9406432	31-03-94	US-A- 5468778	21-11-95
		AU-B- 5102293	12-04-94
EP-A-0286903	19-10-88	AU-B- 607981	21-03-91
		AU-B- 1387088	06-10-88
		DE-A- 3871596	09-07-92
		ES-T- 2042625	16-12-93
		JP-A- 63313728	21-12-88
		US-A- 4952581	28-08-90
EP-A-0364417	18-04-90	AU-B- 625096	02-07-92
		AU-B- 4189889	02-04-90
		DE-D- 68913000	24-03-94
		DE-T- 68913000	16-06-94
		EP-A- 0569046	10-11-93
		ES-T- 2062102	16-12-94
		FI-B- 92690	15-09-94
		HK-A- 159095	20-10-95
		JP-T- 3501025	07-03-91
		WO-A- 9002553	22-03-90
		US-A- 5422369	06-06-95
		US-A- 5422368	06-06-95
		US-A- 5296504	22-03-94
		US-A- 5321128	14-06-94
		SE-A- 8803855	28-10-88

THIS PAGE BLANK (USPTO)